BRIEF published on 02/12/2025 at 07:35, 1 year 4 months ago GenSight Biologics Reports Positive Five-Year Outcomes for LUMEVOQ® Gene Therapy Gene Therapy LUMEVOQ® Visual Acuity Safety Profile REFLECT Study
PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
BRIEF published on 01/23/2025 at 18:50, 1 year 4 months ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 4 months ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
BRIEF published on 01/15/2025 at 07:35, 1 year 5 months ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 5 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 5 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
BRIEF published on 12/24/2024 at 20:51, 1 year 5 months ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 5 months ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
BRIEF published on 11/13/2024 at 07:35, 1 year 7 months ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
Published on 06/18/2026 at 11:30, 28 minutes ago Deadline Extended for 2026 Semmelweis-Richter Journalism Award Applications
Published on 06/18/2026 at 00:00, 11 hours 58 minutes ago LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
Published on 06/17/2026 at 23:30, 12 hours 28 minutes ago Polaris Renewable Energy Announces Postponement of Annual Meeting of Shareholders
Published on 06/17/2026 at 22:50, 13 hours 8 minutes ago International Battery Metals Ltd. Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
Published on 06/17/2026 at 22:30, 13 hours 28 minutes ago Innodata Appoints Jayant Chauhan as Chief Financial Officer
Published on 06/18/2026 at 11:30, 28 minutes ago 2026 Climate Transition Barometer: more than one in two European SMEs and mid-caps gain a tangible competitive advantage from decarbonisation (x3 vs. 2023)
Published on 06/18/2026 at 11:00, 58 minutes ago Mallia Aesthetics Reports Positive Results from Consumer Study with its Hormone-Free 8T3 Essentials Hair Serum
Published on 06/18/2026 at 11:00, 58 minutes ago Traum-Ferienwohnungen Launches Vision 360 to Bring AI-Powered Video Tours to Holiday Homeowners Across Europe
Published on 06/18/2026 at 11:00, 58 minutes ago ABB Ltd: ABB share buybacks - June 11, 2026 – June 17, 2026
Published on 06/18/2026 at 09:06, 2 hours 52 minutes ago Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany
Published on 06/18/2026 at 08:30, 3 hours 28 minutes ago OPmobility wins first awards with Chinese automaker Leapmotor outside of China
Published on 06/18/2026 at 07:00, 4 hours 58 minutes ago bioMérieux introduces Salmonella testing kit on GENE-UP® TYPER to support root cause analysis in the food industry
Published on 06/17/2026 at 17:40, 18 hours 18 minutes ago Report on share repurchases from 10 to 16 June 2026
Published on 06/17/2026 at 08:45, 1 day 3 hours ago Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
